IGM Biosciences, Inc. (IGMS)
After hours:
| Previous close | 9.63 |
| Open | 9.63 |
| Bid | 7.25 x 200 |
| Ask | 9.49 x 200 |
| Day's range | 9.38 - 10.18 |
| 52-week range | 3.81 - 17.70 |
| Volume | |
| Avg. volume | 293,314 |
| Market cap | 559.95M |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.71 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.22 |
ZacksIGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock?
IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Simply Wall St.IGM Biosciences Insiders Placed Bullish Bets Worth US$992.2k
Over the last year, a good number of insiders have significantly increased their holdings in IGM Biosciences, Inc...
GlobeNewswireIGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseasesMOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus ex
